drugset / Trial / NCT00516282

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

NCT00516282

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Temozolomide may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of VNP40101M when given together with temozolomide and to see how well it works in treating patients with progressive or relapsed malignant glioma.

Timeline

Start
2007-08
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 75 mg/m2 Oral
Subject laromustine Other / unclassified 100 mg/m2 Intravenous
Subject laromustine Other / unclassified 125 mg/m2 Intravenous